Sign In
Buy BMY
$56.60
+1.88 (+3.44%)
At Close: Jun 04, 2026
Final Trade: XLE, PANW, XHB, BMY
06:17pm, Thursday, 02'nd Jan 2025
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Is Trending Stock Bristol Myers Squibb Company (BMY) a Buy Now?
10:16am, Tuesday, 31'st Dec 2024
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
2 High-Yield Dividend Stocks to Buy Early in 2025
07:45am, Tuesday, 31'st Dec 2024
The healthcare sector has long been a sanctuary for income investors seeking stability and growth. Within this realm, Bristol-Myers Squibb (BMY -2.81%) and Merck & Co. (MRK -1.33%) stand out for their
Bristol-Myers Squibb Stock: Clearly Undervalued, Excellent 2H24 Culminates In Opdivo 'Subcu' Approval
12:30pm, Monday, 30'th Dec 2024
Bristol-Myers Squibb Stock: Clearly Undervalued, Excellent 2H24 Culminates In Opdivo 'Subcu' Approval
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CheckMate--US FDA Approves Opdivo Qvantig Injection, for Subcutaneous Use in Most Previously Approved Adult, Solid Tumor Opdivo Indications.
US FDA approves injectable form of Bristol Myers' Opdivo
11:35am, Friday, 27'th Dec 2024
The U.S. Food and Drug Administration said on Friday that it has approved an injectable version of Bristol Myers Squibb's blockbuster cancer drug, Opdivo.
Is Bristol Myers Squibb (BMY) Stock Undervalued Right Now?
10:40am, Thursday, 26'th Dec 2024
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
BMY Gets EC Nod for Opdivo Plus Yervoy in First-Line Colorectal Cancer
12:11pm, Tuesday, 24'th Dec 2024
The European Commission approves Bristol Myers' Opdivo plus Yervoy for first-line treatment of MSI-H or dMMR unresectable or metastatic colorectal cancer.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #POETYK--BMS Announces Positive Topline Results from Two Pivotal Phase 3 Trials Evaluating Sotyktu (deucravacitinib) in Adults with Psoriatic Arthritis.
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult.
Want Decades of Passive Income? 3 Stocks to Buy Right Now
04:24am, Saturday, 21'st Dec 2024
Are you looking for reliable long-term investment income? Consider starting your search here, with a closer look at three great dividend stocks that would be at home in nearly any investor's portfolio
Bristol-Myers Squibb: Rich Dividends & Double-Digits Upside Potential - Bright 2026 Prospects
02:00pm, Friday, 20'th Dec 2024
BMY has had a robust H1'24 stock price performance, aided by the July/ August 2024 market rotation and the US FDA timely approval of its acquired schizophrenia therapy. These build upon the 8 new onco
Bristol-Myers Squibb Will Handle The Patent Cliff And Is Still Undervalued
08:00am, Friday, 20'th Dec 2024
Bristol-Myers Squibb remains a "Buy" despite recent price increases, with intrinsic value calculations showing the stock is still undervalued. The company faces risks from patent expirations but has p
Why Bristol Myers Squibb (BMY) Dipped More Than Broader Market Today
06:51pm, Thursday, 19'th Dec 2024
Bristol Myers Squibb (BMY) closed the most recent trading day at $56.30, moving -0.95% from the previous trading session.
3 High-Yielding Dividend Stocks That Retirees Can Rely On for Recurring Income
10:00am, Thursday, 19'th Dec 2024
If you're a retiree and want some dependable income, high-yielding dividend stocks can help make the most of your money. While the average stock on the S&P 500 might pay just an average of 1.2%, there
